David Grayzel

Dave is a partner at Atlas Venture where he has co-founded and led the growth of multiple biotech companies. He was Co-Founder and Chief Executive Officer of Arteaus Therapeutics (acquired by Eli Lilly) and of Annovation Biopharma (acquired by The Medicines Company) and a founding board member of Delinia (acquired by Celgene). Dave is a Co-Founder and Board member of Surface Oncology, Cadent Therapeutics, and Q32 Bio. He also sits on the Board of Xilio Therapeutics. Dave received his B.A. from Stanford University and M.D. from Harvard Medical School.